Toggle navigation
Menu
About Us
Investment Strategy
Team
Portfolio
News
Contact Us
Limited Partners
Portfolio
Symphogen A/S
Develops recombinant antibody mixtures for the treatment and prevention of disease
Transaction Summary
Robust pipeline with development stage candidates across multiple indications
Closed $70M private financing in October 2015 to continue developing pipeline
Results from Phase II trials in 2016 - 2017 a key milestone that could trigger an acquisition of the company
Strong interest from strategics could result in sale of development programs for significant up-front payment plus milestones
Ballerup, Denmark
Contact:
Göran Ando
www.symphogen.com
Related News
Baxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-Oncology
Symphogen and Open Monoclonal Technology Announce Collaboration
Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGa
Symphogen Welcomes Four New Board Members